210 related articles for article (PubMed ID: 10575998)
1. Frequency of bone densitometry for osteoporosis?
Kleerekoper M
Postgrad Med; 1999 Nov; 106(6):22. PubMed ID: 10575998
[No Abstract] [Full Text] [Related]
2. Osteoporosis.
Canfield G
Tenn Med; 2001 Jun; 94(6):211-2. PubMed ID: 11402788
[No Abstract] [Full Text] [Related]
3. [Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Lems WF; Dijkmans BA
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1941-5. PubMed ID: 11048556
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing and managing post menopausal osteoporosis: opportunities for fracture prevention.
McGarry KA; Tammaro D; Cyr MG
Compr Ther; 2003; 29(2-3):115-23. PubMed ID: 14606341
[TBL] [Abstract][Full Text] [Related]
5. Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis.
Lenchik L; Watts NB
J Clin Densitom; 2001; 4(1):1-4. PubMed ID: 11309514
[No Abstract] [Full Text] [Related]
6. Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Kleerekoper M
Geriatrics; 1999 Jul; 54(7):38-43; quiz 44. PubMed ID: 10431598
[No Abstract] [Full Text] [Related]
7. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
[TBL] [Abstract][Full Text] [Related]
8. Medication update.
Slagle MA
South Med J; 2001 Jun; 94(6):574-8. PubMed ID: 11440325
[No Abstract] [Full Text] [Related]
9. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
10. Rheumatology: 15. Osteoporosis.
Wade JP
CMAJ; 2001 Jul; 165(1):45-50. PubMed ID: 11468955
[No Abstract] [Full Text] [Related]
11. [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Kobayashi H; Hamaya E
Nihon Yakurigaku Zasshi; 2005 Jan; 125(1):37-48. PubMed ID: 15738620
[No Abstract] [Full Text] [Related]
12. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.
Lufkin EG; Wong M; Deal C
Rheum Dis Clin North Am; 2001 Feb; 27(1):163-85, vii. PubMed ID: 11285993
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
[TBL] [Abstract][Full Text] [Related]
14. [Diagnosis and pharmacologic therapy of osteoporosis].
Lakatos P
Orv Hetil; 2003 Jul; 144(28):1373-9. PubMed ID: 12914121
[TBL] [Abstract][Full Text] [Related]
15. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
16. [Treatment of osteoporosis].
Lakatos P
Orv Hetil; 2003 Aug; 144(31):1551-2. PubMed ID: 14502870
[No Abstract] [Full Text] [Related]
17. [What do we think about selective estrogen receptor modulators?].
Cortet B
Rev Med Interne; 2001 Dec; 22(12):1173-6. PubMed ID: 11794886
[No Abstract] [Full Text] [Related]
18. Treating osteoporosis in post-menopausal women: a case approach.
Keller MI
Cleve Clin J Med; 2004 Oct; 71(10):829-37. PubMed ID: 15529489
[TBL] [Abstract][Full Text] [Related]
19. The role of SERMs in the management of postmenopausal osteoporosis.
Compston J
J Endocrinol Invest; 1999 Sep; 22(8):646-52. PubMed ID: 10532253
[No Abstract] [Full Text] [Related]
20. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?
Rosenfeld JA
West J Med; 2000 Sep; 173(3):186-8. PubMed ID: 10986186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
